小林制药公司报告26年来首次净利润下降,受到健康问题的补充打击。 Kobayashi Pharmaceutical reports first net profit decline in 26 years, hit by supplement health issues.

小林制药公司报告说,由于与补充药物有关的健康问题,自1999年以来首次出现净利润下降,下降50.5%,降至100亿日元。 Kobayashi Pharmaceutical reported its first net profit decline since 1999, with a 50.5% drop to 10 billion yen, due to health issues linked to its supplements. 该公司的收入下降了4.5%,减至165.6亿日元,并因召回产品和赔偿770多名受影响受害者而面临127亿日元的额外损失。 The company's revenue decreased 4.5% to 165.6 billion yen, and it faced an extra 12.7 billion yen loss from recalling products and compensating over 770 affected victims. 尽管存在这些挑战,但Kobayashi预测下一财政年度的收入为1710亿日元。 Despite these challenges, Kobayashi forecasts a revenue of 171 billion yen for the next fiscal year.